Search research articles
Contact Us
Filters
Showing results (461-470 of 622) with videos related to
Page
of 63
Sort By:
British Journal of Haematology
|
November 28, 2024
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting
Maria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, et al.
The Lancet. Haematology
|
April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2016
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
Elizabeth C Smyth, Matteo Fassan, David Cunningham, et al.
Oncotarget
|
October 22, 2016
Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial
Matthew D Hale, Matthew Nankivell, Gordon G Hutchins, et al.
BMC Cancer
|
March 21, 2023
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
Susanna Slater, Annette Bryant, Hsiang-Chi Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 27, 2022
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens
Jonathan L Moore, Sacheen Kumar, Aida Santaolalla, et al.
BMC Cancer
|
April 26, 2023
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
David K Lau, Caroline Fong, Faten Arouri, et al.
Current Oncology (Toronto, Ont.)
|
April 21, 2022
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study
Fiona Turkes, Annette Bryant, Ruwaida Begum, et al.
The Lancet. Oncology
|
April 13, 2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial
Roger D James, Robert Glynne-Jones, Helen M Meadows, et al.
Cancers
|
May 27, 2026
Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience
Kai Tai Derek Yeung, Simon Gomberg, William Hodgson, et al.
Page
of 63
Search research articles
Search
Showing results (461-470 of 622) with videos related to
Sort By:
Page
of 63
British Journal of Haematology
|
November 28, 2024
Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting
Maria A V Marzolini, Wendi Qian, Laura Clifton-Hadley, et al.
The Lancet. Haematology
|
April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2016
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
Elizabeth C Smyth, Matteo Fassan, David Cunningham, et al.
Oncotarget
|
October 22, 2016
Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial
Matthew D Hale, Matthew Nankivell, Gordon G Hutchins, et al.
BMC Cancer
|
March 21, 2023
ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
Susanna Slater, Annette Bryant, Hsiang-Chi Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 27, 2022
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens
Jonathan L Moore, Sacheen Kumar, Aida Santaolalla, et al.
BMC Cancer
|
April 26, 2023
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
David K Lau, Caroline Fong, Faten Arouri, et al.
Current Oncology (Toronto, Ont.)
|
April 21, 2022
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study
Fiona Turkes, Annette Bryant, Ruwaida Begum, et al.
The Lancet. Oncology
|
April 13, 2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial
Roger D James, Robert Glynne-Jones, Helen M Meadows, et al.
Cancers
|
May 27, 2026
Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience
Kai Tai Derek Yeung, Simon Gomberg, William Hodgson, et al.
Page
of 63